Research presented at ASCO 2025 highlighted potential treatments for patients with newly diagnosed and relapsed or refractory ...

PTCy plus cyclosporine proved more effective than standard GVHD prophylaxis in patients undergoing matched sibling PBSCT in a phase 3 trial.

The program significantly shortens the FDA review time for a sponsor's final drug application submission from approximately 10-12 months to 1-2 months.

An HHS document intended to support the department's change in COVID-19 vaccine policy cites studies that are unpublished or ...

Adding lurbinectedin to atezolizumab as first-line maintenance improved PFS and OS in patients with ES-SCLC in the phase 3 ...

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

The judge's ruling adds to a growing number of legal decisions halting or scaling back the administration’s actions.

Workers at the NIH sent a letter protesting the Trump administration’s cuts to the agency's budget, staff, and research.

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

Children with non-germinomatous germ cell tumors may have better IQ recovery if they receive proton radiotherapy rather than photon radiotherapy.

A survey of more than 20,000 patients revealed a lack of trust in information about cancer, whether it comes from scientists, doctors, or other sources.

Lymphoma research presented at ASCO 2025 highlighted investigational treatments for FL, HL, and DLBCL as well as a revised staging system for NKTCL.